Real Academia Nacional de Farmacia

Últimas Noticias

El Excmo. Sr. D. César Nombela, rector honorario de…

12 Jul 2018

Nos es grato comunicar el nombramiento de nuestro compañero el...

Excmo. Sr. D. Federico Mayor Zaragoza, Presidente Honor de…

14 Jun 2018

La Real Academia Nacionald de Farmacia felicita a su Académico...

Excmo. Sr. D. César Nombela, presidente de Fundación Quaes

14 Jun 2018

La Real Academia Nacional de Farmacia felicita a nuestro Académico...

Destacado

Síguenos en:

RANFTwitterReal Academia
Nacional de Farmacia

Próximas Sesiones

No hay artículos para mostrar

Publicaciones


¿Qué son las enfermedades olvidadas?

Aunque pueda parecer una paradoja, bajo el término enfermedades olvidadas se engloban algunas de las patologías que más matan en el mundo...

Eventos Corporativos

Congresos, Cursos, Presentaciones

galeria

Últimas Sesiones

CONFERENCIA: "FARMACOTECNIA EN LA FARMACIA HOSPITALARIA ESPAÑOLA"

CONFERENCIA: "FARMACOTECNIA EN LA FARMACIA HOSPITALARIA ESPAÑOLA"

Categoría: Conferencias | 14 Jun 2018

El pasado jueves 14 de junio de 2018 a las 19,00 horas la Real Academia Nacional de Farmacia en colaboración con la Fundación José Casares Gil de amigos de la RANF celebraron la CONFERENCIA titulada “FARMACOTECNIA EN LA FARMACIA HOSPITALARIA ESPAÑOLA Evolución Asistencial, Docente e Investigadora 1962 - 2012"  Experiencia personal” Leer más

SESIÓN CIENTÍFICA “LOS RETOS DE LA INDUSTRIA FARMACÉUTICA EN EL NUEVO ENTORNO EUROPEO”.

SESIÓN CIENTÍFICA  “LOS RETOS DE LA INDUSTRIA FARMACÉUTICA EN EL NUEVO ENTORNO EUROPEO”.

Categoría: Mesa Redonda | 13 Jun 2018

El pasado miércoles 13 de junio de 2018 a las 18,00 horas la Real Academia Nacional de Farmacia en colaboración con Farmaindustria celebraon la SESIÓN CIENTÍFICA  “LOS RETOS DE LA INDUSTRIA FARMACÉUTICA EN EL NUEVO ENTORNO EUROPEO”. Leer más

MESA REDONDA "PROBIÓTICOS Y PREBIÓTICOS. EVIDENCIA CIENTÍFICA”

MESA REDONDA "PROBIÓTICOS Y PREBIÓTICOS. EVIDENCIA CIENTÍFICA”

Categoría: Mesa Redonda | 07 Jun 2018

El pasado jueves 7 de Junio de 2018 a las 19,00 horas la Real Academia Nacional de Farmacia en colaboración con la Sociedad Española de Probióticos y Prebióticos (SEPyP) celebraron la MESA REDONDA "PROBIÓTICOS Y PREBIÓTICOS. EVIDENCIA CIENTÍFICA". Leer más

Conferencia: "Biogreografía y bioclimatología de Cabo Verde y Marruecos"

Conferencia: "Biogreografía y bioclimatología de Cabo Verde y Marruecos"

Categoría: Conferencias | 31 May 2018

El pasado jueves 31 de mayo de 2018 a las 19,00 horas la Real Academia nacional de Farmacia en colaboración con la Fundación José Casares Gil, de Amigos de la RANF celebraron la CONFERENCIA titulada: “Biogeografia y bioclimatología de Cabo Verde y Marruecos" Leer más

Nussenzweig, Michael C.

 Name: Michel C. Nussenzweig
Date of Birth: February 10, 1955
Education:
1975 B.A. - New York University College of Arts and Sciences
1981 Ph.D. - The Rockefeller University
1982 M.D. - New York University School of Medicine
Clinical Training:
1982-1985 Intern & Resident, Internal Medicine, Clinical Fellow, Infectious Diseases Massachusetts General Hospital
Postdoctoral Training:
1986-1989 Harvard Medical School, Department of Genetics
Professional Appointments
1990-1996 Assistant & Associate Professor, The Rockefeller University
1990-1999 Assistant & Associate Investigator, Howard Hughes Medical Institute
1996-present Professor & Senior Physician, The Rockefeller University
1999-present Investigator, Howard Hughes Medical Institute
2000-2013 Sherman Fairchild Professor, The Rockefeller University
2013-present Zanvil A. Cohn & Ralph M. Steinman Professor, The Rockefeller University

For his groundbreaking work demonstrating broad and potent neutralizing antibodies to HIV-1 and establishing that they are a safe and effective immunotherapeutic for infected humans.
Nussenzweig is responsible for key insights into dendritic and B cell function. With Steinman, he opened the field of antigen presentation by DCs by discovering that they capture, process and present antigens to initiate immunity. He produced the first DC-monoclonal antibody that was essential in establishing their role in immune responses and cloned the first endocytic receptor expressed by DCs. Using these reagents he developed a method to deliver antigens to DCs in vivo, leading to the discoveries that in steady state, DCs maintain peripheral tolerance and that different DC subsets have distinct antigen processing capacities. He resolved the long-standing problem of how DCs are related to and diverge from other myeloid cells including monocytes during development in the bone marrow. In recognition of his work with Steinman, Nussenzweig was chosen to deliver the 2011 Nobel lecture in Steinman's place.
As a fellow with Leder, he used transgenic mice to show that membrane bound antibodies regulate allelic exclusion and lymphocyte development. Nussenzweig's discovery that antibody class switching activates the DNA damage response opened up a new area of B cell biology. He established the importance of the DNA double strand break response to resolution of the class switch reaction and demonstrated that the same DNA lesions that initiate switching can also lead to oncogenic chromosome translocations between antibody genes and c-myc.
Antibodies are the essential protective elements of nearly all vaccines. In the last several years' antibodies have also become important therapeutic agents in treating inflammation and cancer. Nussenzweig's research is on the development and function of antibodies and on the B-lymphocytes that produce them. He developed robust and scalable methods for the cloning of antibody genes from single human B cells. He first applied this approach to define how tolerance develops in normal individuals and later to the HIV-1 antibody problem.
Nussenzweig made a ground breaking advance in this area when he uncovered broad and potent neutralizing antibodies to HIV-1. His work, and that of others that rapidly adopted his methods, led to the discovery of naturally arising anti-HIV antibodies that were orders of magnitude more potent than previously known antibodies. Moreover, they revealed novel targets of HIV-1 vulnerability. The new antibodies neutralized up to 95% of all HIV-1 strains individually, and nearly all known strains when combined even at very low concentrations. Nussenzweig established that these antibodies both prevent and control chronic infection in humanized mice and in macaques. He then confirmed the pre-clinical studies in phase 1 clinical trials in humans. His clinical experiments established that antibodies are a safe and effective for HIV-1 prevention and therapy.
He is a Howard Hughes Investigator, a fellow of the American Academy of Arts and Sciences, the Brazilian Academy of Sciences, a member of the National Academy of Medicine USA, and the National Academy of Sciences USA.

Fecha de ingreso 11/04/2016
Discurso de ingreso

 "An Immunologist's View of the HIV Problem"

 Ver Sesión

Presentación:

Excmo. Sr. D. Mariano Esteban Rodríguez

Presentación

Sesiones Destacadas

Calendario de Actividades

Julio 2018
Lu Ma Mi Ju Vi Sa Do
25 26 27 28 29 30 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31 1 2 3 4 5

Fundación Casares Gil

La Fundación José Casares Gil de Amigos de la RANF, tiene la finalidad de ayudar a la Real Academia Nacional de Farmacia a desarrollar sus actividades.

Más información

Medalla Carracido

Es nuestra máxima condecoración y premia a personas o entidades jurídicas por su contribución relevante a la ciencia farmacéutica y c.c. afines a la farmacia.

Más información

Hazte Socio

haztesocio

Logos

Información de Contacto · Real Academia Nacional de Farmacia

Dirección: Calle de la Farmacia 9-11.

28004 Madrid. España. ver mapa

Teléfonos: +34915310307 / +34 915 223 147   |   Fax: +34 915 310 306   |   Correo: Contacto por Email

Horario: Lunes a Jueves (no festivos) de 9:30h a 14:30h y de 15:30h a 21:30h.

Acceso or Registro

LOG IN

Registro

User Registration